Tuesday
09.17.2019
12:10 PM
Login form
Search
Calendar
«  June 2013  »
SuMoTuWeThFrSa
      1
2345678
9101112131415
16171819202122
23242526272829
30
Entries archive

My site

Main » 2013 » June » 23
New Phase III data presented at the American Diabetes Association 73rd Scientific Sessions® (ADA) showed linagliptin improved blood glucose control as monotherapy and in combination with metformin, in Asian people from China, Malaysia and the Philippines with Type 2 Diabetes.

INGELHEIM, Germany & INDIANAPOLIS, US - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- For Non-US and Non-UK Media

Boehringer Ingelheim and Eli Lilly and Company today presented results from two randomised Phase III clinical trials evaluating the efficacy and safety of linagliptin in Asians from China, Malaysia and the Philippines with Type 2 Diabetes (T2D). The results showed that adults with T2D treated with linagliptin both as monotherapy and in combination with metformin achieved improved blood glucose control compared with placebo.

The rate of Type 2 Diabetes is rapidly increasing in Asia with the present trend indicating that more than 60% of the world’s diabeti ... Read more »
Views: 82 | Added by: uaeonlinenews | Date: 06.23.2013 | Comments (0)

Data presented at the American Diabetes Association 73rd Scientific Sessions® also showed reduction in required insulin dose in treated study subjects

INGELHEIM, Germany & Indianapolis, US - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE/ME NewsWire)-- For Non-US and Non-UK Media

Boehringer Ingelheim and Eli Lilly and Company today announced results of a 78-week Phase III clinical trial of the investigational compound empagliflozin* as an add-on to basal insulin in people with Type 2 Diabetes (T2D). The study, presented at the American Diabetes Association (ADA) 73rd Scientific Sessions®, showed that empagliflozin 10mg and 25mg, produced statistically significant reductions in HbA1c (average blood glucose), compared to placebo as add-on to basal insulin, at the time of assessment Data presented at the American Diabetes Association 73rd Scientific Sessions® also showed reduction in required insulin dose in treated study subjects

of the ... Read more »
Views: 80 | Added by: africa-live | Date: 06.23.2013 | Comments (0)

Data presented at American Diabetes Association 73rd Scientific Sessions® also showed reductions in weight and blood pressure


INGELHEIM, Germany & INDIANAPOLIS, US - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- For Non-US and Non-UK Media

Boehringer Ingelheim and Eli Lilly and Company today announced results of a 52-week Phase III clinical trial of the investigational compound empagliflozin*, which showed statistically significant reductions in HbA1c (average blood glucose) at week 24, with the addition of empagliflozin to existing oral glucose-lowering therapy in people with Type 2 Diabetes (T2D) and mild to moderate renal impairment as measured by the estimated glomerular filtration rate (eGFR ≥60 to <90mL/min/1.73m2 and eGFR ≥30 to <60mL/min/1.73 m2).1

Empagliflozin is a member of the sodium glucose cotransporter 2 (SGLT2) inhibitor class of drugs and is being investigated for the reduction of blood glucose levels in adults ... Read more »
Views: 67 | Added by: uaeonlinenews | Date: 06.23.2013

Active clamp structure prevents overvoltage when inductive load is switched off

TOKYO - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- Toshiba Corporation (TOKYO: 6502) today announced that it has launched a MOSFET, "SSM3K337R", for relay drivers. The new device uses an active clamp structure that prevents overvoltage when the inductive load of relay devices is switched off. Sample is available and mass production is scheduled to start in September. Demand for relay drivers is growing for automobile, since the number of electric components equipped by automobile is increasing. The "SSM3K337R" reduces ON-resistance by half and improves allowable power dissipation to approximately 1.6 times that of equivalent products.
 

Key Features

1.
          

Active clamp structure reduces stress by inductive load of relay devices.

2.
          

ON-resistance ... Read more »
Views: 90 | Added by: uaeonlinenews | Date: 06.23.2013

Data presented at the American Diabetes Association 73rd Scientific Sessions® also showed reduction in body weight and systolic blood pressure in treated study subjects

INGELHEIM, Germany & INDIANAPOLIS, US - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE/ME NewsWire)-- For Non-US and Non-UK Media

Boehringer Ingelheim and Eli Lilly and Company today announced results of a 24-week Phase III clinical trial, which showed that treatment with the investigational compound empagliflozin* as monotherapy produced statistically significant reductions in HbA1c (average blood glucose) versus placebo, in patients with Type 2 Diabetes (T2D) who had not received any treatment for at least 12 weeks prior to randomisation.1

Empagliflozin is a member of the sodium glucose cotransporter 2 (SGLT2) inhibitor class of drugs and is being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess gluc ... Read more »
Views: 90 | Added by: africa-live | Date: 06.23.2013 | Comments (0)

Data presented at the American Diabetes Association (ADA) 73rd Scientific Sessions® provides insights for use of Trajenta® (linagliptin) in adults with Type 2 Diabetes (T2D) with moderate to severe renal impairment

INGELHEIM, Germany & INDIANAPOLIS, US - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- For Non-U.S. and Non-UK media

Boehringer Ingelheim and Eli Lilly and Company today announced results from a new study that demonstrated linagliptin showed statistically significant reduction in blood glucose levels (HbA1C) in adult patients with Type 2 Diabetes (T2D) with moderate to severe renal impairment (RI), compared with those receiving placebo (12 weeks). Most patients had T2D for more than ten years (76%) and were on insulin (86%). After 12 weeks, patients on placebo switched to glimepiride up to 52 weeks. The study found that patients treated with linagliptin had lower rates of hypoglycaemia and less weight gain than those who received g ... Read more »
Views: 105 | Added by: uaeonlinenews | Date: 06.23.2013 | Comments (0)

Study Shows Sequential Compression Sleeves Reduce DVT Events in Immobile Stroke Patients

MANSFIELD, Mass. - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that an independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien’s Kendall SCD™ system with Vascular Refill Detection Technology on immobile stroke patients.

The results of the CLOTS 3 trial were presented at the European Stroke Conference by Professor Martin S. Dennis of the University of Edinburgh’s Division of Clinical Neurosciences and also published in The Lancet. The new study showed a 29.9% decrease in the development of proximal deep vein thrombosis (DVT) in immobile stroke patients who received intermittent pneumatic compression (IPC) using the Kendall SCD system with Vascular Refill Detection Technology, which delivers sequential, circumferentia ... Read more »
Views: 121 | Added by: uaeonlinenews | Date: 06.23.2013

Data presented at the American Diabetes Association 73rd Scientific Sessions® also showed statistically significant reductions in mean daily glucose and body weight in treated study subjects

INGELHEIM, Germany and INDIANAPOLIS, US - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- For Non-US and Non-UK Media

Boehringer Ingelheim and Eli Lilly and Company today announced results of two Phase III 24-week clinical trials of the investigational compound empagliflozin* added to metformin with and without the addition of sulphonylurea, respectively, in people with Type 2 Diabetes (T2D). These results showed statistically significant reductions in blood glucose among people who received empagliflozin, as measured by reductions in HbA1c (average blood glucose) after 24 weeks.1,2

Empagliflozin is a member of the sodium glucose cotransporter 2 (SGLT2) inhibitor class of drugs and is being investigated for the reduction of blood glucose levels in adults wi ... Read more »
Views: 125 | Added by: africa-live | Date: 06.23.2013

New Functionality Streamlines Workflow, Speeds Results and Improves Patient Safety

RESEARCH TRIANGLE PARK, N.C. - Saturday, June 22nd 2013 [ME NewsWire]

DIA 2013

(BUSINESS WIRE)-- Quintiles today announced new functionality that improves laboratory management for investigator sites, delivered by its award-winning Quintiles Infosario® technology platform. Infosario seamlessly combines data, processes and Quintiles’ therapeutic expertise to enable faster, better-informed decisions across the drug development lifecycle. With Infosario, investigators and site personnel now have the ability to order tests, track samples and view results within one secure, online portal.

"The investigators working with Quintiles’ Global Laboratory network can now experience the benefits of streamlined communications, improved data accuracy and accelerated laboratory tests results,” said Thomas Wollman, Senior Vice President, Quintiles Global Laboratories and Cardiac Safety Se ... Read more »
Views: 112 | Added by: uaeonlinenews | Date: 06.23.2013

Brand President Charlie Denson to retire in 2014

BEAVERTON, Ore. - Friday, June 21st 2013 [ME NewsWire]

(BUSINESS WIRE)-- NIKE, Inc. (NYSE: NKE) announced today that Charlie Denson, NIKE Brand President since 2006 and a 34-year veteran of the brand, will retire in January 2014. In conjunction with Denson’s decision to retire, the Company also announced strategic changes in its executive management team as part of the Company’s long-term organizational strategy to align the business to continue to drive growth. The changes reflect the Company’s focus on the consumer by accelerating innovation, elevating design, aligning product and merchandising excellence, optimizing go-to-market strategies and sharpening focus on supply chain and manufacturing capabilities.

Effective July 1, 2013, Trevor Edwards, currently the EVP of Brand and Category Management, will become the new NIKE Brand President leading all category and geographic business units, the Jordan Brand, Action ... Read more »
Views: 69 | Added by: africa-live | Date: 06.23.2013

Study to Compare Traditional Negative Pressure Wound Therapy to V.A.C. VeraFlo™ Instillation Therapy, using the V.A.C.Ulta™ Negative Pressure Wound Therapy System

SAN ANTONIO - Thursday, June 20th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Kinetic Concepts, Inc. announced today the initiation of patient enrollment in a multi-center clinical study assessing the benefits of negative pressure wound therapy (NPWT) with intermittent instillation therapy with a topical wound cleanser. The randomized, controlled prospective study involves six investigative centers across the United States and compares traditional NPWT with V.A.C.® Negative Pressure Wound Therapy to adjunctive treatment with V.A.C. VeraFlo™ Instillation Therapy using the V.A.C.Ulta™ Negative Pressure Wound Therapy System for wounds that require hospital admission and serial surgical debridement.

This study follows an independent retrospective, historical cohort-controlled study recently presented at the 201 ... Read more »
Views: 108 | Added by: africa-live | Date: 06.23.2013

GE Healthcare to provide a quality solution with affordable costs while broadening mammography portfolio by acquiring Value Digital Mammography The acquisition represents GE Korea’s growth strategy, "In Korea, For the World” Win-win partnership will create a platform for Rayence to enter overseas markets achieved through the supply contract of CMOS detector

SEOUL, Korea - Friday, June 21st 2013 [BUSINESS WIRE/ ME NewsWire]

(BUSINESS WIRE)-- GE Healthcare (NYSE: GE) today announced that it has agreed to acquire certain Mammography assets of Rayence, a subsidiary of Vatech Co Ltd (KOSDAQ: 043150), a Korean X-Ray manufacturer. The Mammography assets of Rayence will, at closing, become part of the Detection & Guidance Solutions (DGS) business unit of GE Healthcare.

Given the dynamic emerging healthcare market, this acquisition is strategically significant as it will allow GE Healthcare to expand its mammography product range to the Value Mammography segment, estim ... Read more »
Views: 132 | Added by: uaeonlinenews | Date: 06.23.2013